Travere Therapeutics Inc.

19.27
0.00 (0.00%)
At close: Mar 13, 2025, 11:40 AM

Travere Therapeutics Statistics

Share Statistics

Travere Therapeutics has 88.74M shares outstanding. The number of shares has increased by 14.37% in one year.

Shares Outstanding 88.74M
Shares Change (YoY) 14.37%
Shares Change (QoQ) 13.78%
Owned by Institutions (%) 99.99%
Shares Floating 87.38M
Failed to Deliver (FTD) Shares 446
FTD / Avg. Volume 0.03%

Short Selling Information

The latest short interest is 9.58M, so 11% of the outstanding shares have been sold short.

Short Interest 9.58M
Short % of Shares Out 11%
Short % of Float 11.15%
Short Ratio (days to cover) 7.3

Valuation Ratios

The PE ratio is -4.27 and the forward PE ratio is -104.46. Travere Therapeutics's PEG ratio is -0.02.

PE Ratio -4.27
Forward PE -104.46
PS Ratio 5.89
Forward PS 1.5
PB Ratio 23.26
P/FCF Ratio -4.06
PEG Ratio -0.02
Financial Ratio History

Enterprise Valuation

Travere Therapeutics Inc. has an Enterprise Value (EV) of 1.01B.

EV / Earnings -3.15
EV / Sales 4.35
EV / EBITDA -3.82
EV / EBIT -3.16
EV / FCF -2.99

Financial Position

The company has a current ratio of 2.08, with a Debt / Equity ratio of 6.8.

Current Ratio 2.08
Quick Ratio 2.04
Debt / Equity 6.8
Total Debt / Capitalization 87.18
Cash Flow / Debt -0.59
Interest Coverage -28.67

Financial Efficiency

Return on equity (ROE) is -5.44% and return on capital (ROIC) is -69.63%.

Return on Equity (ROE) -5.44%
Return on Assets (ROA) -0.54%
Return on Capital (ROIC) -69.63%
Revenue Per Employee $605,649.35
Profits Per Employee $-835,181.82
Employee Count 385
Asset Turnover 0.39
Inventory Turnover n/a

Taxes

Income Tax 120K
Effective Tax Rate 0

Stock Price Statistics

The stock price has increased by 133.5% in the last 52 weeks. The beta is 0.75, so Travere Therapeutics's price volatility has been higher than the market average.

Beta 0.75
52-Week Price Change 133.5%
50-Day Moving Average 20.14
200-Day Moving Average 14.69
Relative Strength Index (RSI) 44.53
Average Volume (20 Days) 1.6M

Income Statement

In the last 12 months, Travere Therapeutics had revenue of 233.18M and earned -321.55M in profits. Earnings per share was -4.08.

Revenue 233.18M
Gross Profit 233.18M
Operating Income -320.63M
Net Income -321.55M
EBITDA -265.77M
EBIT -320.63M
Earnings Per Share (EPS) -4.08
Full Income Statement

Balance Sheet

The company has 58.53M in cash and 401.58M in debt, giving a net cash position of -343.05M.

Cash & Cash Equivalents 58.53M
Total Debt 401.58M
Net Cash -343.05M
Retained Earnings -1.45B
Total Assets 594.13M
Working Capital 215.95M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -237.47M and capital expenditures -101.21M, giving a free cash flow of -338.69M.

Operating Cash Flow -237.47M
Capital Expenditures -101.21M
Free Cash Flow -338.69M
FCF Per Share -4.29
Full Cash Flow Statement

Margins

Gross margin is 100%, with operating and profit margins of -137.51% and -137.9%.

Gross Margin 100%
Operating Margin -137.51%
Pretax Margin -137.45%
Profit Margin -137.9%
EBITDA Margin -113.98%
EBIT Margin -137.51%
FCF Margin -145.25%

Dividends & Yields

TVTX does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Payout Ratio n/a
Earnings Yield -21.44%
FCF Yield -20.06%
Dividend Details

Analyst Forecast

The average price target for TVTX is $32, which is 68.2% higher than the current price. The consensus rating is "Buy".

Price Target $32
Price Target Difference 68.2%
Analyst Consensus Buy
Analyst Count 14
Stock Forecasts

Stock Splits

The last stock split was on Nov 2, 2012. It was a backward split with a ratio of 1:9.

Last Split Date Nov 2, 2012
Split Type backward
Split Ratio 1:9

Scores

Altman Z-Score -2.52
Piotroski F-Score 4